Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan

被引:172
|
作者
Miyakawa, Shuichi [1 ]
Ishihara, Shin [1 ]
Horiguchi, Akihiko [1 ]
Takada, Tadahiro [2 ]
Miyazaki, Masaru [3 ]
Nagakawa, Takukazu [4 ]
机构
[1] Fujita Hlth Univ, Dept Biliary & Pancreat Surg, Toyoake, Aichi 4701192, Japan
[2] Teikyo Univ, Dept Surg, Tokyo 173, Japan
[3] Grad Sch Med, Dept Gen Surg, Chiba, Japan
[4] Fukuno Hosp, Nanto, Toyama, Japan
来源
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2009年 / 16卷 / 01期
关键词
Biliary tract cancer; Statistics registry; 5-year survival; Stage of disease; Lymph node metastasis; LONG-TERM SURVIVAL; AMPULLARY CARCINOMAS; GALLBLADDER CANCER; SURGERY; CHOLANGIOCARCINOMA; GUIDELINES; MANAGEMENT; RECURRENCE; VATER; EXPERIENCE;
D O I
10.1007/s00534-008-0015-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The results from the Japanese Biliary Tract Cancer Statistics Registry from 1988 to 1998 were reported in 2002. In the present study, we report here selectively summarized data as an overview of the 2006 follow-up survey of the registered cases from 1998 to 2004 for information bearing on problems with the treatment of cancer of the biliary tract. A total of 5,584 patients were registered from 1998 to 2004. The site of cancer was the bile duct in 2,732 patients, the gallbladder in 2,067, and the papilla of Vater in 785. Those cases were analyzed with regard to patient survival according to the extent of tumor invasion (pT), the extent of lymph node metastasis (pN) and the stage. The five-year survival rate after surgical resection was 33.1% for bile duct cancer, 41.6% for gallbladder cancer, and 52.8% for cancer of the papilla of Vater. For hilar or superior bile duct cancer, the 5-year survival rate was lower with an increase in the pT, pN and f stage, except pT3 vs. pT4, pN1 vs. pN2 and stage III vs. stage IVa. For middle or distal bile duct cancer, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT2 vs. pT3, pN2 vs. pN3, stage II vs. stage III and stage III vs. stage IVa. For gallbladder cancer, the 5-year survival rate was lower with increase in pT, pN and f stage. For cancer of the papilla of Vater, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT1 vs. pT2, pN1 vs. pN2, and stage III vs. stage IVa. In the present study, the outcomes of surgical treatment were better than that of the previous report from Japan and foreign countries. The pT, pN and stage of gallbladder cancer are well defined. However, there were no significant differences in some groups of those of bile duct cancer and cancer of the papilla of Vater.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] Emerging molecular target antagonists for the treatment of biliary tract cancer
    Lombardi, Pasquale
    Marino, Donatella
    Fenocchio, Elisabetta
    Chila, Giovanna
    Aglietta, Massimo
    Leone, Francesco
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (01) : 63 - 75
  • [22] A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
    Ramjeesingh, Ravi
    Chaudhury, Prosanto
    Tam, Vincent C.
    Roberge, David
    Lim, Howard J.
    Knox, Jennifer J.
    Asselah, Jamil
    Doucette, Sarah
    Chhiber, Nirlep
    Goodwin, Rachel
    CURRENT ONCOLOGY, 2023, 30 (08) : 7132 - 7150
  • [23] The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer
    Gkika, Eleni
    Hawkins, Maria A.
    Grosu, Anca-Ligia
    Brunner, Thomas B.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] Current systemic treatment for advanced biliary tract cancer
    Vogel, Arndt
    Saborowski, Anna
    ONKOLOGIE, 2022, 28 (04): : 287 - 298
  • [25] Contribution of immunotherapy in the treatment of advanced biliary tract cancer
    Delaye, Matthieu
    Lievre, Astrid
    Neuzillet, Cindy
    BULLETIN DU CANCER, 2022, 109 (11) : 11S11 - 11S20
  • [26] Systemic treatment of advanced or recurrent biliary tract cancer
    Zhang, Wei
    Zhou, Hongyuan
    Wang, Yingying
    Zhang, Zewu
    Cao, Guangtai
    Song, Tianqiang
    Zhang, Ti
    Li, Qiang
    BIOSCIENCE TRENDS, 2020, 14 (05) : 328 - 341
  • [27] Biliary tract cancer: our experience with gemcitabine treatment
    Verderame, F
    Mandina, P
    Abruzzo, F
    Scarpulla, M
    Di Leo, R
    ANTI-CANCER DRUGS, 2000, 11 (09) : 707 - 708
  • [28] Molecular-driven treatment for biliary tract cancer: the promising turning point
    Persano, Mara
    Puzzoni, Marco
    Ziranu, Pina
    Pusceddu, Valeria
    Lai, Eleonora
    Pretta, Andrea
    Donisi, Clelia
    Pinna, Giovanna
    Spanu, Dario
    Cimbro, Erika
    Parrino, Alissa
    Liscia, Nicole
    Mariani, Stefano
    Dubois, Marco
    Migliari, Marco
    Scartozzi, Mario
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1253 - 1264
  • [29] Current systemic treatment for advanced biliary tract cancer
    Vogel, Arndt
    Saborowski, Anna
    ONKOLOGE, 2022, 28 (04): : 287 - 298
  • [30] Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey
    Isohashi, Fumiaki
    Ogawa, Kazuhiko
    Oikawa, Hirobumi
    Onishi, Hiroshi
    Uchida, Nobue
    Maebayashi, Toshiya
    Kanesaka, Naoto
    Tamamoto, Tetsuro
    Asakura, Hirofumi
    Kosugi, Takashi
    Uno, Takashi
    Ito, Yoshinori
    Karasawa, Katsuyuki
    Takayama, Makoto
    Manabe, Yoshihiko
    Yamazaki, Hideya
    Takemoto, Mitsuhiro
    Yoshioka, Yasuo
    Nemoto, Kenji
    Nishimura, Yasumasa
    RADIATION ONCOLOGY, 2013, 8